Amgen's Positive Bone Drug Data Missed Some High Expectations - Wall Street Journal
Amgen's Positive Bone Drug Data Missed Some High ExpectationsWall Street JournalNonetheless, the data should support the drug's potential approval in this usage next year, likely adding annual sales of more than $1 billion in addition ...and more��
No comments:
Post a Comment